Ahead of discussions on the European Union's future Framework Program for Research and Innovation (FP10), the region’s leading pharma trade body has given its view.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has proposed nine key recommendations aimed at maximizing the program’s impact.
“Implementing these recommendations would not only optimize the investment in research and innovation but also position the EU at the forefront of health R&I globally,” said Magda Chlebus, executive director of science policy and regulatory affairs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze